Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients
Chronic idiopathic diarrhea is a common complaint of patients presenting to family practitioners and internists, and is one of the most common reasons for referral to gastroenterologists. It is estimated that the prevalence of chronic idiopathic diarrhea in developed countries (including the
The primary objective of the Study will be to evaluate the safety and efficacy of crofelemer in patients with chronic idiopathic diarrhea. Adult patients with a diagnosis of noninfectious chronic idiopathic diarrhea (defined as >20 bowel movements per week of which >50% are watery bowel movements) will be included in the Study. Subjects will receive crofelemer (Mytesi) 125 mg delayed-release tablets twice daily, with or without food for four weeks. Reduction in weekly stool frequency as well as changes in stool consistency and quality of life improvements will be evaluated at the end of the Study.
The principal investigator for the Study will be Dr.
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.